ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO276

Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Hendry, Bruce M., Travere Therapeutics Inc, San Diego, California, United States
  • Kohan, Donald E., University of Utah Health, Salt Lake City, Utah, United States
  • Geletka, Rob, Travere Therapeutics Inc, San Diego, California, United States
  • Jenkinson, Celia P., Travere Therapeutics Inc, San Diego, California, United States
  • Chen, Charles, Travere Therapeutics Inc, San Diego, California, United States
  • Bedard, Patricia W., Travere Therapeutics Inc, San Diego, California, United States

In the PROTECT study, sparsentan, which targets both the endothelin type A (ETAR) and angiotensin type 1 (AT1R) receptors, reduced proteinuria vs active comparator in IgA nephropathy with minimal changes in fluid status. This contrasts with greater fluid retention, including heart failure hospitalization, in studies using agents targeting ETAR alone (ERA). This may relate to differences in comorbidities; however, aspects of dual receptor binding by sparsentan may also be a factor. Since ETAR blockers favor fluid retention while AT1R blockers may promote fluid excretion, continual high blockade of AT1R during ETAR blockade may help maintain normal fluid balance. The pharmacokinetic (PK) properties of sparsentan were used to estimate diurnal changes in receptor occupancy (RO) at steady state in the PROTECT study.


Receptor affinities (Ki) were determined for sparsentan at ETAR, ETBR, and AT1R using radioligand binding assays. PopPK modeling of sparsentan was used to derive 24-hour PK and RO profile of patients in PROTECT.


Sparsentan receptor affinities and PK data of a typical IgAN patient in the PROTECT study are shown in Fig. 1A. The 24-hour plot of sparsentan RO for ETAR, ETBR, and AT1R using PK data estimated for 400 mg daily shows RO is ~60%-90% for ETAR, >95% for AT1R, and <1% for ETBR (Fig. 1B).


Sparsentan has a stable 24-hour relationship in relative RO of ETAR to AT1R in which AT1R RO always exceeds ETAR RO. In contrast, when a drug solely targets ETAR, on top of AT1R blockade, periods of relatively unaccompanied ETAR antagonism may occur, representing a risk for fluid retention. This could partly explain the fluid retention seen with ERA and the minimal changes in fluid status seen with sparsentan.

Fig 1: (A) Sparsentan receptor binding parameters and steady-state mean PK estimates from the PROTECT study. (B) Sparsentan receptor occupancies (right axis) over 24 hours for a single daily 400 mg oral dose in the PROTECT study, steady-state mean exposure (left axis).


  • Commercial Support – Travere Therapeutics, Inc.